Bacterin International Holdings, Inc. has signed a national distribution agreement with Spartan Medical, Inc.
Bacterin Signs Distribution Agreement for Military Facilities

A March 10, 2015 announcement from Bacterin says Spartan Medical will distribute Bacterin’s proprietary product portfolio of bone graft materials to medical centers affiliated with the U.S. Department of Defense (DoD) and the U.S. Department of Veteran’s Affairs (VA). Spartan Medical is a “service-disabled, veteran-owned, small business focused on distribution to government medical facilities.”
“Spartan Medical is constantly on the lookout for the best products in the world that will improve surgical outcomes for those who have served, ” said Vince Proffitt, president of Spartan Medical. “Our relationship with Bacterin does just that and makes our Biologics offering second to none.”
Melanie Head, Bacterin’s vice president of sales added, “Our new relationship with Spartan Medical is both a great privilege and wonderful opportunity. It will enable us to provide our military personnel, soldiers and veterans with the biologics they deserve to enhance the quality of their lives, while also adding another experienced distribution channel to our organization.”
Spartan Medical, according to the announcement, was founded in 2008 by a former Air Force Intelligence Officer “in an effort to provide an extensive armamentarium of advanced medical devices and technologies focused on the needs of the VA and DoD Surgeon.” To date, the company has secured multi-year Blanket Purchase Agreements at 30 major military treatment facilities.
Bacterin is an accredited tissue bank and medical device company. The company will be in booth 2316 at the upcoming annual meeting of the American Academy of Orthopaedic Surgeons taking place in Las Vegas from March 24 to the 28, 2015. The company will be highlighting its newest allograft family, 3Demin Cortical Fibers, Boats, and Strips.

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.